Investors

Investors

麒麟加速器为啥登录上-outline

Horizon is a biopharmaceutical company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients.  We believe science and compassion must work together to transform lives. 
 
Horizon's global headquarters is in Dublin, Ireland.  The Company also has offices in Lake Forest, Ill.; Chicago, Ill.; Brisbane, Calif.; Novato, Calif.; Washington, D.C. and Mannheim, Germany.

麒麟加速器为啥登录上-outline

Aug 5, 2024
8:00 AM EDT

麒麟加速器为啥登录上-outline

Add to Outlook
Add to Google Calendar

麒麟加速器为啥登录上-outline

Volume:

Refresh Quote

麒麟加速器为啥登录上-outline

Date Title
07/31/20
Summary ToggleNew Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
赛·风3安卓下载
Summary ToggleTarget Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout
07/13/20
Summary ToggleHorizon Therapeutics plc to Release Second-Quarter 2024 Financial Results and Host Webcast on Aug. 5, 2024
TEPEZZA® Presentation
ESG Overview (2024 Proxy)
赛 风破解版 下载
Investor Presentation
赛 风破解版 下载

麒麟加速器为啥登录上-outline

Investor Contacts Tina Ventura
Senior Vice President,
Investor Relations
Investor-relations@horizontherapeutics.com

Ruth Venning
Executive Director,
Investor Relations
Investor-relations@horizontherapeutics.com
賽风安卓版百度云 Geoff Curtis
Executive Vice President,
Corporate Affairs & Chief
Communications Officer
media@horizontherapeutics.com
+1 888 506-2562
Ireland Media Contact Ray Gordon
Gordon MRM
ray@gordonmrm.ie
+353 (87) 2417373
Shareholder Tools

麒麟加速器为啥登录上-outline

  • Email Alerts Subscription
  • RSS News Feeds
  • Snapshot
  • Print